HLG Genomics Files for KOSDAQ Listing at 21,500 Won, Eyes July 24 Debut With 667:1 Subscription Ratio

According to Seoul Kyungje, HLG Genomics, a subsidiary of Hanrim Pharmaceutical specializing in active pharmaceutical ingredients (APIs), will list on Korea's KOSDAQ market on July 24 with an offer price of 21,500 Korean won at the top end of the target range (18,500–21,500 won). The company's general public subscription recorded a competition ratio of 667.23 to 1, attracting approximately 4.6 trillion Korean won in deposit funds. First-day trading is expected to range between 12,900 and 86,000 won, or 60–400% above the offer price.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments